The special role of ultrasound for screening, staging and surveillance of malignant ovarian tumors: Distinction from other methods of diagnostic imaging

Archives of Gynecology and Obstetrics

Volumn 289, Issue 3, 2014, Pages 491-498

  Manegold Brauer, Gwendolin ^a   Bellin, Anjeung Kang ^b   Tercanli, Sevgi ^b   Lapaire, Olav ^a   Heinzelmann Schwarz, Viola ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Practice for Prenatal Diagnostics and Gynecologic Ultrasound   (Switzerland)

Author keywords

Adnexal mass; Diagnostic imaging; Ovarian cancer; Staging ovarian cancer; Transvaginal ultrasound

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADNEXA DISEASE; ADNEXAL MASS; ARTICLE; CANCER MORPHOLOGY; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ECHOGRAPHY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PATIENT ASSESSMENT; PREOPERATIVE PERIOD; SENSITIVITY AND SPECIFICITY; TRANSVAGINAL ECHOGRAPHY; TUMOR DIFFERENTIATION;

CONTRAST MEDIA; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MASS SCREENING; NEOPLASM STAGING; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84896702033     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-013-3081-8     Document Type: Article

References (53)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18(3):581-592
2. Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, Stewart C, Friedlander M, Fox S, Bowtell D, Mitchell G (2012) BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group. J Clin Oncol 30(21):2654-2656
3. Earle CC, Schrag D, Neville BA, Yabroff KR, Topor M, Fahey A, Trimble EL, Bodurka DC, Bristow RE, Carney M, Warren JL (2006) Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 98(3):172-180
4. Engelen MJ, van der Zee AG, de Vries EG, Willemse PH (2006) Debulking surgery for ovarian epithelial cancer performed by a gynaecological oncologist improved survival compared with less specialised surgeons. Cancer Treat Rev 32(4):320-323
5. Woo YL, Kyrgiou M, Bryant A, Everett T, Dickinson HO (2012) Centralisation of services for gynaecological cancers - a Cochrane systematic review. Gynecol Oncol 126(2):286-290
6. Valentin L, Ameye L, Testa A, Lécuru F, Bernard JP, Paladini D, Van Huffel S, Timmerman D (2006) Ultrasound characteristics of different types of adnexal malignancies. Gynecol Oncol 102(1):41-48
7. Sharma A, Apostolidou S, Burnell M, Campbell S, Habib M, Gentry-Maharaj A, Amso N, Seif MW et al (2012) Risk of epithelial ovarian cancer in asymptomatic women with ultrasound-detected ovarian masses: a prospective cohort study within the UK collaborative trial of ovarian cancer screening (UKCTOCS). Ultrasound Obstet Gynecol 40(3):338-344
8. Timmerman D, Valentin L, Bourne TH, Collins WP, Verrelst H, Vergote I, International Ovarian Tumor Analysis (IOTA) Group (2000) Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the international ovarian tumor analysis (IOTA) group. Ultrasound Obstet Gynecol 16(5):500-505
9. Timmerman D, Testa AC, Bourne T, Ameye L, Jurkovic D, Van Holsbeke C, Paladini D, Van Calster B, Vergote I, Van Huffel S, Valentin L (2008) Simple ultrasound-based rules for the diagnosis of ovarian cancer. Ultrasound Obstet Gynecol 31(6):681-690
10. Geomini P, Kruitwagen R, Bremer GL, Cnossen J, Mol BW (2009) The accuracy of risk scores in predicting ovarian malignancy: a systemic review. Obstet Gynecol 113(2 Pt 1):384-394
11. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG (1990) A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynecol 97(10):922-929
12. Chia YN, Marsden DE, Robertson G, Hacker NF (2008) Triage of ovarian masses. Aust N Z J Obstet Gynaecol 48(3):322-328
13. Timmerman D, Testa AC, Bourne T, Ferrazzi E, Ameye L, Konstantinovic ML, Van Calster B, Collins WP, Vergote I, Van Huffel S, Valentin L (2005) Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the international ovarian tumor analysis group. J Clin Oncol 23(34):8794-8801
14. Valentin L, Hagen B, Tingulstad S, Eik-Nes S (2001) Comparison of 'pattern recognition' and logistic regression models for discrimination between benign and malignant pelvic masses: a prospective cross validation. Ultrasound Obstet Gynecol 18(4):357-365
15. Van Holsbeke C, Van Calster B, Bourne T, Ajossa S, Testa AC, Guerriero S, Fruscio R, Lissoni AA, Czerkierdowski A, Savelli L, Van Huffel S, Valentin L, Timmerman D (2012) External validation of diagnostic models to estimate the risk of malignancy in adnexal masses. Clin Cancer Res 18(3):815-825
16. Van Calster B, Timmerman D, Valentin L, McIndoe A, Ghaem-Maghami S, Testa AC, Vergote I, Bourne T (2012) Triaging women with ovarian masses for surgery: observational diagnostic study to compare RCOG guidelines with an international ovarian tumour analysis (IOTA) group protocol. BJOG 119(6):662-671
17. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC Jr, Skates SJ (2009) A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 112(1):40-46
18. Urban N, Thorpe JD, Bergan LA, Forrest RM, Kampani AV, Scholler N, O'Briant KC, Anderson GL, Cramer DW, Berg CD, McIntosh MW, Hartge P, Drescher CW (2011) Potential role of HE4 in multimodal screening for epithelial ovarian cancer. J Natl Cancer Inst 103(21):1630-1634
19. Karlsen MA, Sandhu N, Høgdall C, Christensen IJ, Nedergaard L, Lundvall L, Engelholm SA, Pedersen AT, Hartwell D, Lydolph M, Laursen IA, Høgdall EV (2012) Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecol Oncol 127(2):379-383
20. Jacob F, Meier M, Caduff R, Goldstein D, Pochechueva T, Hacker N, Fink D, Heinzelmann-Schwarz V (2011) No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol 121(3):487-491
21. Campbell S (2012) Ovarian cancer: role of ultrasound in preoperative diagnosis and population screening. Ultrasound Obstet Gynecol 40(3):245-254
22. Reade CJ, Riva JJ, Busse JW, Goldsmith CH, Elit L (2013) Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis. Gynecol Oncol 130(3):674-681
23. Long KC, Kauff ND (2013) Screening for familial ovarian cancer: a ray of hope and a light to steer by. J Clin Oncol 31(1):8-10
24. Mohaghegh P, Rockall AG (2012) Imaging strategy for early ovarian cancer: characterization of adnexal masses with conventional and advanced imaging techniques. Radiographics 32(6):1751-1773
25. Timmerman D, Schwärzler P, Collins WP, Claerhout F, Coenen M, Amant F, Vergote I, Bourne TH (1999) Subjective assessment of adnexal masses with the use of ultrasonography: an analysis of interobserver variability and experience. Ultrasound Obstet Gynecol 13:11-16
26. Dodge JE, Covens AL, Lacchetti C, Elit LM, Le T, Devries-Abound M, Fung-Kee-Fung M, Gynecology Cancer Disease Site Group (2012) Management of a suspicious adnexal mass: a clinical practice guideline. Curr Oncol 19(4):244-257
27. Kinkel K, Lu Y, Mehdizade A, Pelte MF, Hricak H (2005) Indeterminate ovarian mass at US: incremental value of second imaging test for characterization-meta-analysis and Bayesian analysis. Radiology 236(1):85-94
28. Bharwani N, Reznek RH, Rockall AG (2011) Ovarian cancer management: the role of imaging and diagnostic challenges. Eur J Radiol 78(1):41-51
29. Alt CD, Brockner KA, Eichbaum M, Sohn C, Arnegger FU, Kauczor HU, Hallscheidt P (2011) Imaging of female pelvic malignancies regarding MRI, CT, and PET/CT: part 2. Strahlenther Onkol 187(11):705-714
30. Basu S, Kwee TC, Surti S, Akin EA, Yoo D, Alavi A (2011) Fundamentals of PET and PET/CT imaging. Ann N Y Acad Sci 1228:1-18
31. Nishizawa S, Inubushi M, Ozawa F, Kido A, Okada H (2007) Physiological FDG uptake in the ovaries after hysterectomy. Ann Nucl Med 21(6):345-348
32. Zhu ZH, Cheng WY, Cheng X, Dang YH (2007) Characteristics of physiological uptake of uterus and ovaries on 18F-fluorodeoxyglucose positron emission tomography. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 29(1):124-129
33. Iyer RB, Balachandran A, Devine CE (2007) PET/CT and cross sectional imaging of gynecologic malignancy. Cancer Imaging 7 (Spec No A):S130-S138
34. Castellucci P, Perrone AM, Picchio M, Ghi T, Farsad M, Nanni C, Messa C, Meriggiola MC, Pelusi G, Al-Nahhas A, Rubello D, Fazio F, Fanti S (2007) Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology. Nucl Med Commun 28(8):589-595
35. Risum S, Høgdall C, Loft A, Berthelsen AK, Høgdall E, Nedergaard L, Lundvall L, Engelholm SA (2007) The diagnostic value of PET/CT for primary ovarian cancer - a prospective study. Gynecol Oncol 105(1):145-149
36. Yamamoto Y, Oguri H, Yamada R, Maeda N, Kohsaki S, Fukaya T (2008) Preoperative evaluation of pelvic masses with combined 18F-fluorodeoxyglucose positron emission tomography and computed tomography. Int J Gynaecol Obstet 102(2):124-127
37. Nam EJ, Yun MJ, Oh YT, Kim JW, Kim JH, Kim S, Jung YW, Kim SW, Kim YT (2010) Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI. Gynecol Oncol 116(3):389-394
38. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS, European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363(10):943-953
39. Forstner R (2007) Radiological staging of ovarian cancer: imaging findings and contribution of CT and MRI. Eur Radiol 17(12):3223-3235
40. Fischerova D (2011) Ultrasound scanning of the pelvis and abdomen for staging of gynecological tumors: a review. Ultrasound Obstet Gynecol 38(3):246-266
41. Testa AC, Bourne TH (2009) Characterising pelvic masses using ultrasound. Best Pract Res Clin Obstet Gynaecol 23(5):725-738
42. Fischerova D, Cibula D, Dundr P, Zikan M, Freitag P, Slama J, Calda P (2008) The role of ultrasound in prediction of optimal versus suboptimal cytoreductive surgery in advanced ovarian cancers OC 132: 18th World congress on ultrasound in obstetrics and gynecology. Ultrasound Obstet Gynecol 32:243-307
43. Uzan C, Kane A, Rey A, Gouy S, Pautier P, Lhomme C, Duvillard P, Morice P (2011) How to follow up advanced-stage borderline tumours? Mode of diagnosis of recurrence in a large series stage II-III serious borderline tumours of the ovary. Ann Oncol 22(3):631-635
44. Zanetta G, Rota S, Lissoni A, Meni A, Brancatelli G, Buda A (2001) Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors. Gynecol Oncol 81(1):63-66
45. ®
46. Woodward PJ, Hosseinzadeh K, Saenger JS (2004) From the archives of the AFIP: radiologic staging of ovarian carcinoma with pathologic correlation. Radiographics 24(1):225-246
47. Forstner R, Hricak H, Occhipinti KA, Powell CB, Frankel SD, Stern JL (1995) Ovarian cancer: staging with CT and MR imaging. Radiology 197(3):619-626
48. Tempany CM, Zou KH, Silverman SG, Brown DL, Kurtz AB, McNeil BJ (2000) Staging of advanced ovarian cancer: comparison of imaging modalities - report from the radiological diagnostic oncology group. Radiology 215(3):761-767
49. Coakley FV, Choi PH, Gougoutas CA, Pothuri B, Venkatraman E, Chi D, Bergman A, Hricak H (2002) Peritoneal metastases: detection with spiral CT in patients with ovarian cancer. Radiology 223(2):495-499
50. Sebastian S, Lee SI, Horowitz NS, Scott JA, Fischman AJ, Simeone JF, Fulle AF, Hahn PF (2008) PET-CT versus CT alone in ovarian cancer recurrence. Source Abdomen Imaging 33(1):112-118
51. Markman M (2009) Optimal management of recurrent ovarian cancer. Int J Gynecol Cancer 19(Suppl 2):S40-S43
52. Murakami M, Miyamoto T, Iida T, Tsukada H, Watanabe M, Shida M, Maeda H, Nasu S, Yasuda S, Yasuda M, Ide M (2006) Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer. Int J Gynecol Cancer 16(1):99-107
53. Thrall MM, DeLoia JA, Gallion H, Avril N (2007) Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol Oncol 105(1):17-22